JOHN N MELEK

Allopathic & Osteopathic Physicians|Internal Medicine DALLAS, TX NPI 1316248503

General Payments — all program years on this page

$970.42

  • Category: General Payments
  • Program years: PY2021–2024
  • Record count: 51
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $413.00 across 20 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Food and Beverage $413.0020

By paying entity

Latest program year (PY2024) · sorted by reported total.

Paying entityAmountRecords
Acerta Pharma LLC $212.7710
Lilly USA, LLC $75.704
Abbott Laboratories $37.592
Novo Nordisk AS $36.362
Sumitomo Pharma America, Inc. $27.381
Amgen Inc. $23.201

By program year

Program yearAmountRecords
2021 $57.363
2022 $200.5012
2023 $299.5616
2024 $413.0020

Records — PY2024 (20)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1096616432 Novo Nordisk Inc $19.34 03/18/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1096863114 Novo Nordisk Inc $17.02 08/22/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104328564 AstraZeneca Pharmaceuticals LP $64.61 01/10/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104423281 AstraZeneca Pharmaceuticals LP $16.52 09/12/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104487700 AstraZeneca Pharmaceuticals LP $14.59 06/19/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104530724 AstraZeneca Pharmaceuticals LP $16.17 06/11/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105543453 AstraZeneca Pharmaceuticals LP $16.28 08/27/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105651448 AstraZeneca Pharmaceuticals LP $15.88 04/01/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105685831 AstraZeneca Pharmaceuticals LP $15.42 10/22/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105698080 AstraZeneca Pharmaceuticals LP $17.50 05/07/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105701296 AstraZeneca Pharmaceuticals LP $14.79 05/21/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105753733 AstraZeneca Pharmaceuticals LP $21.01 02/13/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1117326227 Amgen Inc. $23.20 02/20/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1124983774 Abbott Laboratories $17.22 11/11/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1124983777 Abbott Laboratories $20.37 08/14/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1135051850 Lilly USA, LLC $16.78 05/09/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1135053426 Lilly USA, LLC $24.40 03/26/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1135053428 Lilly USA, LLC $19.46 09/26/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1135069261 Lilly USA, LLC $15.06 06/24/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1148889899 Sumitomo Pharma America, Inc. $27.38 04/11/2024 Food and Beverage Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.